🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

RecruitingPhase 2Ages 18 Years - anyAllCentre Paul Strauss
NCT05653635 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age \> 18 years * Glioblastoma, World Health Organization (WHO) grade IV, histologically proven * Performance status 0, 1 or 2 * Neurological status ≥ 2 * Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm) * Radiological proven recurrence according to 1 and 2 criteria, Wen et al * Remaining node after partial surgery post-recurrence * 1 to 3 recurrence site(s) \< 35 mm in wide axis and separated by at least 5 mm * Volume of each lesion \< 35 mL * Distance between recurrence node(s) and optic nerves (left and right), chiasma and/or cerebral trunk \> 10 mm Exclusion Criteria: * Patient with contraindication to MRI or PET * Glioblastomatose * Pregnancy or breastfeeding * Patient that do not understand French * Patient without affiliation to the national or local social security * Patients not able to comply to the protocol assessments for geographic, social or psychological reasons * Minor or patients placed under guardianship or supervision * Patients deprived of liberty * Patients placed under judicial protection * Patients that are not able to express their consent
💊

What it tests

  • Simultaneous-integrated boost with IMRT
📍

Where

2 sites
CHRU de Nancy
Nancy, France
Centre Paul Strauss
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy